Cancer, early symptom signs

@Campbellteaching Learn more about your ad choices. Visit megaphone.fm/adchoices

Bivalent new vaccine, Moderna press releaseUploaded 19-08-22https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Omicron-Containing-Bivalent-Booster-Candidate-mRNA-1273.214-Demonstrates-Superior-Antibody-Response-Against-Omicron/default.aspxOmicron-containing bivalent COVID booster candidate, mRNA-1273.214(original mRNA-1273 vaccine),Superior neutralizing antibody responsein baseline seronegative participants. increased neutralizing geometric mean titers (GMT) against Omicron approximately 8-fold above baseline levels. mRNA-1273.214 50 μg booster dose, well-tolerated in the 437 study participantsThe safety and reactogenicity profile of the mRNA-1273.214 50 μg booster dose was similar to that of mRNA-1273 50 μgBA.1SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 44 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1093275/covid-technical-briefing-44-22-july-2022.pdfBA.2 3.4% BA.4 17.2% BA.5 78.7%Other 0.7%US variantshttps://covid.cdc.gov/covid-data-tracker/#variant-proportionsBA.5 88.8%BA.4 5.3%BA.4.6 5.1%BA.2.12.1 0.8%BA.2 0%BA.1s 0%Delta 0%Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canadahttps://jamanetwork.com/journals/jamanetworkopen/fullarticle/2793551Population-based cohort study of 297 individuals in Ontario, Canada,with myocarditis or pericarditis following COVID-19 vaccination,found higher rates of myocarditis or pericarditis associated with receipt of mRNA-1273 compared with BNT162b2 as a second dose, particularly among male individuals aged 18 to 24 years. The results suggest that there may be product-specific differences in rates of myocarditis or pericarditis after receiving mRNA vaccinesFirst bivalent COVID-19 booster vaccine approved by UK medicines regulatorhttps://www.gov.uk/government/news/first-bivalent-covid-19-booster-vaccine-approved-by-uk-medicines-regulatorModerna bivalent approved for adult booster doses by MHRASpikevax bivalent Original/Omicron25 micrograms targets the original virus strain25 micrograms targets OmicronOmicron (BA.1) and the original 2020 strain(was also found to generate a good immune response against BA.4 and BA.5)Safety monitoringside effects observed were the same as those seen for the original Moderna booster dose,and were typically mild and self-resolving, and no serious safety concerns were identified.Global covid deathshttps://www.worldometers.info/coronavirus/6,466,947Evidence cited by HMRAhttps://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2822%2900320-6/fulltextBased on official reported COVID-19 deaths, we estimated that vaccinations prevented 14·4 million deaths from COVID-19 in 185 countries,between Dec 8, 2020, and Dec 8, 2021. 19·8 million when we used excess deaths as an estimateJoint Committee on Vaccination and Immunisation (JCVI) updated statement on the COVID-19 vaccination programme for autumn 2022For autumn 2022https://www.gov.uk/government/publications/jcvi-updated-statement-on-the-covid-19-vaccination-programme-for-autumn-2022/joint-committee-on-vaccination-and-immunisation-jcvi-updated-statement-on-the-covid-19-vaccination-programme-for-autumn-2022JCVI advisesthe following groups should be offered a COVID-19 booster vaccine:residents in a care home for older adults and staff working in care homes for older adultsfrontline health and social care workersall adults aged 50 years and overpersons aged 5 to 49 years in a clinical risk group persons aged 5 to 49 years who are household contacts of people with immunosuppressionpersons aged 16 to 49 years who are carers Time to collect PROSPECT Learn more about your ad choices. Visit megaphone.fm/adchoices

Confirmation of excess deaths in 2023 for US, UK, Canada, Australia, NZ, Netherlands, and Denmark. However, deaths are lower than expected in Poland, Hungary, and Sweden. Uploaded 24-09-23OECD datahttps://stats.oecd.org/index.aspx?queryid=104676 Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

Viral replication is reduced in the lung tissue, but increased in the bronchi. This could indicate increased transmissibility but reduced pathogenicity.

UK case surge has started, R is 3 to 5